Scientific Decision Intelligence
Artificial intelligence can generate more medical hypotheses than the scientific world could ever test. HISTAMOS was built to solve the next bottleneck: selection.
We use accumulated lessons from successful and failed experiments, biological mechanisms, scientific evidence and connections across diseases to help determine:
HISTAMOS is not another AI model, a laboratory, a drug company or a consulting firm built around one expert's opinion.
It is a scientific decision-intelligence system being developed in Germany.
We use AI, statistics and biomedical data as tools.
HISTAMOS continuously learns from:
what worked · what failed · why it failed · what the biology actually showed · and whether the same lesson appears elsewhere in the human body
Make every experiment improve the next decision.
AI changed scientific research. Generating hypotheses is becoming extremely fast.
Testing them is not.
Laboratories remain limited by:
time · people · samples · patients · equipment · and capital
Even the largest pharmaceutical company cannot physically test every plausible idea AI can generate.
The scarce resource is no longer ideas.
It is knowing which ideas deserve a real experiment.
That is the problem HISTAMOS addresses.
You may have dozens, hundreds or thousands of plausible hypotheses. Your laboratory may be able to test only a few. HISTAMOS helps prioritize which scientific directions deserve scarce experimental resources.
A hypothesis portfolio, biological question or set of possible experiments.
Which ideas deserve priority, which are weak enough to eliminate early, and which experiment is most likely to produce useful new information.
Drug development decisions can determine where years of work and tens of millions in capital will go next. HISTAMOS provides an independent scientific challenge before major investment.
A drug program, target, therapeutic hypothesis, failed program or proposed next development step.
See below.
The direction deserves further investment.
The opportunity may remain valuable, but the current strategy should change.
The current direction does not justify further investment.
The evidence is not yet strong enough to decide.
If the next development stage costs €20 million, discovering a fundamental weakness before spending those €20 million can be enormously valuable.
The same applies in the opposite direction: a program that survives rigorous challenge earns a stronger scientific basis for continued investment.
Researchers rarely lack ideas. They lack unlimited time and funding. HISTAMOS helps research groups compare competing explanations, identify missing evidence and prioritize the questions most likely to move the science forward.
A difficult hypothesis, unresolved mechanism, proposed experiment or scientific program.
What is known, what is still assumed, what evidence is missing and what question deserves to be tested next.
Healthcare organizations already have enormous amounts of patient data. More data alone does not guarantee a better decision. HISTAMOS helps organize longitudinal clinical information and scientific evidence to identify where patient differences may warrant closer professional attention or reassessment.
A defined patient-care problem and appropriate clinical data.
Where meaningful differences appear, which cases deserve closer review, where uncertainty remains and what deserves reassessment.
For example, in an organization managing €1 billion in annual medical spending, a 0.25% improvement in avoidable cost represents:
€2.5 million per year
At 0.5%:
€5 million per year
Illustrative examples only — not HISTAMOS performance forecasts.
Patient health comes first. The treating physician remains the medical decision-maker.
We then discovered something important. A leading cancer research group headed by Professor Christopher Lord had already independently established the same core biological vulnerability through conventional experimental science.
That scientific direction subsequently advanced into Phase II clinical investigation.
HISTAMOS did not discover it before Professor Lord. That is not the claim.
From hundreds of AI-generated possibilities, our system independently prioritized the scientific direction that experienced researchers had already judged strong enough to take toward clinical testing.
This case is documented in our published research.
Read the Case Study →A scientific system that always finds an opportunity is not useful.
In another test using randomized clinical-trial data, HISTAMOS evaluated whether a more sophisticated treatment-selection strategy added useful decision value.
It did not.
No convenient subgroup was created afterward to rescue the idea.
Finding what deserves investment matters.
So does identifying what does not.
We do not claim to know kidney medicine better than a world-class nephrologist.
We do not claim to know oncology better than an oncology research laboratory.
And we do not replace experimental scientists.
Specialists go deep. HISTAMOS is designed to connect and accumulate.
Medicine is divided into:
A lesson discovered in one disease may expose an important pattern in another.
A failed cancer experiment may reveal a scientific error that should not be repeated in kidney research.
A biological mechanism discovered in diabetes may change how another disease is understood.
HISTAMOS preserves these lessons and tests whether they travel.
One body. Connected biology. Accumulated scientific learning.
AI is one of our tools. So is statistics. So are scientific publications and experimental data.
But AI can generate thousands of plausible answers.
AI asks:
"What might be possible?"
HISTAMOS asks:
"Which possibility has earned the right to consume a real experiment?"
Founder & Scientific Lead
HISTAMOS was built from the conviction that the scientific method itself can be systematized — not to replace researchers, but to make every experiment they run more valuable than the last.
With a background spanning biomedical research, statistical decision theory, and systems engineering, Mohammed leads HISTAMOS from Germany with a focus on rigorous, evidence-based scientific selection.
You do not need to buy a large platform.
You do not need to accept our claims.
Bring HISTAMOS:
We perform a bounded evaluation.
You receive a clear scientific decision package:
If we add no meaningful value, stop there.
If we do, we build the next step together.
Challenge HISTAMOS →